Business Context and Reporting Period
This Form 8-K is a current report filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on May 27, 2022. The filing addresses Item 5.02 regarding the departure of a senior officer and the appointment of an interim replacement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and personnel changes.
Material Changes
- Resignation of CFO: Thomas Reilly, Chief Financial Officer, resigned effective on or about June 15, 2022, to pursue a new opportunity. The departure is not due to any dispute with the Company.
- Interim Appointment: Richard Makara, Vice President, Head of Accounting & Controller, will assume the responsibilities of CFO, Principal Financial Officer, and Principal Accounting Officer on an interim basis immediately following Mr. Reilly's departure.
- Compensatory Arrangement: Upon assuming interim duties, Mr. Makara will receive a grant of 7,500 restricted stock units (RSUs). These will vest on the earlier of December 31, 2022, or the appointment of a permanent successor, contingent on continuous employment.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of market risks. The primary contingency noted is the ongoing search for a permanent replacement for the Chief Financial Officer.
Investor Verification Checklist
- Verify the exact effective date of Thomas Reilly's resignation (on or about June 15, 2022).
- Confirm the vesting schedule and conditions for the 7,500 RSUs granted to Richard Makara.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Note that the company name in the metadata request ("Tvardi Therapeutics") differs from the registrant in the filing ("Cara Therapeutics, Inc.").